How do YOU get the word out?

Share your story!

Let us know how you helped protect your patients. Just complete the fields below and submit!



Enter your e-mail address: *
Confirm your e-mail address: *
Share your story: *

By submitting this information, I agree that CSL Biotherapies may choose to add these comments to the Afluria.com website. However, CSL Biotherapies agrees to keep all personally identifiable information confidential.
I would like to be contacted periodically with information about Afluria^® and special offers from CSL Biotherapies. Prior to submitting your information, please review our Privacy Policy.

CSL Biotherapies
Address: P.O.Box 61501
1020 First Avenue
King of Prussia, PA 19406 USA
Phone: 610-878-4000
Fax: 610-878-4009

Customer Service
Phone: 800-655-3396
Fax: 610-878-4888

Medical Affairs
Phone: 800-504-5434
Fax: 610-878-4007

Important Safety Information

Afluria^® is indicated for active immunization of persons 18 years of age and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. The indication is based on the immune response elicited by Afluria^®; no controlled clinical studies have demonstrated a decrease in influenza disease after vaccination with Afluria^®.

Afluria^® should not be administered to individuals with hypersensitivity to eggs or chicken protein or other components of Afluria^®, or to anyone who has had a life-threatening reaction to previous influenza vaccination. The most common injection-site adverse reactions were tenderness, pain, redness, and swelling. The most common systemic adverse reactions were headache, malaise, and muscle aches.

Vaccination with Afluria^® may not protect all individuals. Immunocompromised persons may have a diminished immune response. If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give Afluria^® should be based on careful consideration of the potential benefits and risks.

Click here for full PRESCRIBING INFORMATION.